Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).

4 Sep 2009

First artificial heart implant successfully performed by a AUBMC medical team

A medical team at the American University of Beirut Medical Center (AUBMC) has successfully performed the first artificial heart implant in Lebanon, saving the life of a 37-year-old man suffering from terminal heart failure.

4 Sep 2009

Covidien's Sleep Diagnostic business acquired by Embla

Embla and Covidien have entered into a definitive agreement under which Embla will acquire Covidien's Sleep Diagnostic business. This includes the sleep diagnostic products sold under the Sandman(TM) brand name. Financial terms of the transaction were not disclosed. Completion of the sale is subject to customary closing conditions.

4 Sep 2009

CRT-D implants for treating sudden cardiac death

Electrophysiologists Robert Stevenson, MD, and Jeffrey L. Williams, MD, MS, FACC, are safely implanting cardiac resynchronization therapy defibrillators in the Good Samaritan Hospital (GSH) Cardiology (Heart Failure) Program.

3 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

m.pulse system for MCP therapy installed in ten hospitals

Cardiola AG announced today that it has placed its patented m.pulse system in 10 hospitals located in Germany and Switzerland, on the heels of the system’s CE-Mark approval. MCP was previously only available in a clinical setting. Now, m.pulse is the world’s first and only device enabling CAD patients to receive MCP therapy at home.

3 Sep 2009

Survey on the current routine practice in CRT implantations in patients with heart failure

The European cardiac resynchronization therapy (CRT) Survey is a joint initiative taken by the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology. Its primary objective is to describe current European practice and routines associated with the implantation of a CRT device with or without an ICD (implantable cardioverter defibrillator) capability in patients with heart failure.

2 Sep 2009

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

MADIT-CRT trial reveals reduced risk of heart failure from CRT-D therapy

Asymptomatic or mildly symptomatic cardiac patients randomised to an implanted cardiac resynchronisation device with defibrillator (CRT-D) have a 34% lower risk of heart failure or death than those receiving a standard implanted cardioverter defibrillator (ICD-only) (HR 0.66,>

2 Sep 2009

Defibrillator-cardiac resynchronization therapy combination reduces heat failure risk

Patients who had a cardiac resynchronization device combined with a defibrillator (CRT-D) implanted had a 34 percent reduction in their risk of death or heart failure when compared to patients receiving only an implanted cardiac defibrillator (ICD), according to a landmark study published online today in the New England Journal of Medicine and presented today at the European Society of Cardiology Congress (ESC) in Barcelona, Spain.

2 Sep 2009

Current European practice and routines associated with the implantation of a CRT device described

2 Sep 2009

Telemedical supervision for chronic heart failure patients reduces hospital expenses

The current data confirms previous health economic evaluations: If patients with chronic heart failure are receive telemedical supervision, this means that they will require less and shorter hospital care. In this study hospital expenses dropped by around 70 percent in a year.

2 Sep 2009

PROTECT clinical study aimed at the assessment of rolofylline effects

Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.

2 Sep 2009

New therapy delays the progression of heart failure

A therapy called cardiac resynchronization can significantly delay the progression of heart failure, according to a major international study published in the New England Journal of Medicine.

2 Sep 2009

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

2 Sep 2009

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

In a major international trial, researchers from McMaster University in Canada, found that the hypertension drug irbesartan reduced the risk of heart failure complications and the combination of stroke, other embolic events and transient ischemic events, also known as ministrokes, in patients with atrial fibrillation.

2 Sep 2009

Patient enrollment completed for the Berlin Heart EXCOR Pediatric IDE clinical study

Berlin Heart Inc. reported today that it has completed enrollment in Cohort 1 of the Berlin Heart EXCOR(R) Pediatric IDE Study after having received unconditional approval of the study from the FDA in November 2008.

2 Sep 2009

First AbioCor Total Replacement Heart recipient does not survive

Abiomed, Inc. (NASDAQ: ABMD), has been informed by Mark Anderson, M.D., associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at both the medical school and Robert Wood Johnson University Hospital, that the first patient to receive the commercial AbioCor Total Replacement Heart, died on August 23, 2009, due to post-operative conditions unrelated to the device.

1 Sep 2009

Telemonitoring systems enable early detection of silent, asymptomatic arrhythmias in heart

An increasing number of heart failure patients are treated with a number of complex devices, i.e. cardiac resynchronization therapy (CRT). Recently completed and ongoing clinical trials such as MADIT-CRT and EchoCRT provide evidence of a growing number of CRT patients, in need of individualised treatment.

1 Sep 2009

Atrial fibrillation ablation - one of the fastest growing cardiology techniques

Atrial fibrillation ablation is one of the fastest growing techniques in cardiology and due to the very high number of patients that might be candidates to this procedure, a significant number of resources will have to be devoted to it to be able to treat them in the following years.

1 Sep 2009

Heart Failure News and Research

Further Reading

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

First artificial heart implant successfully performed by a AUBMC medical team

Covidien's Sleep Diagnostic business acquired by Embla

CRT-D implants for treating sudden cardiac death

Millennium's sNDA to be reviewed by the FDA

m.pulse system for MCP therapy installed in ten hospitals

Survey on the current routine practice in CRT implantations in patients with heart failure

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

MADIT-CRT trial reveals reduced risk of heart failure from CRT-D therapy

Defibrillator-cardiac resynchronization therapy combination reduces heat failure risk

Current European practice and routines associated with the implantation of a CRT device described

Telemedical supervision for chronic heart failure patients reduces hospital expenses

PROTECT clinical study aimed at the assessment of rolofylline effects

New therapy delays the progression of heart failure

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

Patient enrollment completed for the Berlin Heart EXCOR Pediatric IDE clinical study

First AbioCor Total Replacement Heart recipient does not survive

Telemonitoring systems enable early detection of silent, asymptomatic arrhythmias in heart

Atrial fibrillation ablation - one of the fastest growing cardiology techniques

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News